Loading clinical trials...
Loading clinical trials...
Phase 1b/2, Multicenter, Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies
Conditions
Interventions
oprozomib
Locations
19
United States
Mayo Clinic Scottsdale
Scottsdale, Arizona, United States
Pacific Cancer Care
Salinas, California, United States
Colorado Blood Cancer Institute
Denver, Colorado, United States
Mayo Clinic
Jacksonville, Florida, United States
Winship Cancer Institute, Emory University
Atlanta, Georgia, United States
Rush University Medical Center
Chicago, Illinois, United States
Start Date
October 15, 2011
Primary Completion Date
August 8, 2016
Completion Date
August 12, 2019
Last Updated
November 8, 2022
NCT07249528
NCT06215118
NCT06679101
NCT05969860
NCT06870760
NCT06383143
Lead Sponsor
Amgen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions